To report the efficacy of oral HIF-2α inhibitor belzutifan in participants with von Hippel-Lindau disease-associated retinal hemangioblastomas in LITESPARK-004.
Subgroup analysis of the phase 2, single-arm, open-label LITESPARK-004 study.
Adults with ≥1 von Hippel-Lindau disease-associated measurable renal cell carcinoma tumor not requiring immediate surgical intervention were eligible.
Participants received oral belzutifan 120 mg once daily until disease progression or unacceptable treatment-related toxicity.
Efficacy of belzutifan in retinal hemangioblastomas was a secondary end point, measured as response (improved, stable, or progressed) by independent reading center certified graders based on color fundus imaging performed every 12 weeks using the investigator's preferred imaging standards. Additional assessments, where available, included optical coherence tomography and ultra-widefield fluorescein angiography.
Among 61 participants in LITESPARK-004, 12 had ≥1 evaluable active retinal hemangioblastoma in 16 eyes at baseline per independent reading center. As of April 1, 2022, the median follow-up for participants with ocular von Hippel-Lindau disease at baseline was 37.3 months. All 16 eyes were graded as improved, with a response rate of 100.0% (95% confidence intervals, 79.4-100.0). No new retinal hemangioblastomas or ocular disease progression were reported as of data cutoff date. Eight participants had additional multimodal eye assessments performed at the National Institutes of Health study site. Among this subgroup, 10 of 24 hemangioblastomas in 8 eyes of 6 participants measured ≥500 μm in greatest linear dimension at baseline and were further analyzed. All 10 hemangioblastomas had a mean area reduction of ≥15% by month 12 and ≥30% by month 24.
Belzutifan showed promising activity against ocular von Hippel-Lindau disease, including capacity to control retinal hemangioblastomas, with effects sustained for >2 years while on treatment.
Ophthalmology. 2024 Jun 05 [Epub ahead of print]
Henry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, Jay Chhablani, Ane Bundsbæk Bøndergaard Iversen, Anders Kruse, Eric Jonasch, Dan S Gombos, Tobias Else, Hakan Demirci, Benjamin L Maughan, M Elizabeth Hartnett, Hanna R Coleman, Wei Fu, Rodolfo F Perini, Yanfang Liu, W Marston Linehan, Emily Y Chew, LITESPARK-004 Investigator Group – Ocular VHL
National Eye Institute, National Institutes of Health, Bethesda, MD, USA (currently at Genentech, Inc., South San Francisco, CA, USA)., Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., University of Pittsburgh, Pittsburgh, PA, USA., Aarhus University Hospital, Aarhus, Denmark., Aalborg University Hospital, Aalborg, Denmark., The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Section of Ophthalmology, Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA., University of Michigan, Ann Arbor, MI, USA., University of Utah, Salt Lake City, UT, USA., University of Utah, Salt Lake City, UT, USA;; Byers Eye Institute at Stanford University, Palo Alto, CA, USA., VOIANT (Independent Reading Center), Boston, MA USA., Merck & Co., Inc., Rahway, NJ, USA., National Eye Institute, National Institutes of Health, Bethesda, MD, USA (currently at Genentech, Inc., South San Francisco, CA, USA). Electronic address: .